Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 8 months ago

Heart Failure

MI/ACS
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 10 months ago

Heart Failure
Emerging Strategies in Aldosterone Inhibition: A Special Focus
Author(s): Vijay Chopra Added: 1 month ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps… View more

Heart Failure
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 1 month ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
Finerenone: Will It Be a Game-changer?
Author(s): Dinesh Khullar , Anish Kumar Gupta , Kulwant Singh Added: 6 months ago

Cardiovascular Renal Metabolic

Heart Failure
ESC 24: MRAs in Heart Failure
Author(s): Added: 10 months ago
ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT… View more

Heart Failure
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 10 months ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Heart Failure

Prevention & Chronic Conditions
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 8 months ago

Heart Failure

Prevention & Chronic Conditions
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 6 months ago

Heart Failure

Prevention & Chronic Conditions
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 7 months ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure